Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
23.80
+0.76 (3.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Dianthus Therapeutics Employees
Dianthus Therapeutics had 53 employees as of December 31, 2023. The number of employees increased by 21 or 65.63% compared to the previous year.
Employees
53
Change (1Y)
21
Growth (1Y)
65.63%
Revenue / Employee
$101,245
Profits / Employee
-$1,265,887
Market Cap
704.41M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 53 | 21 | 65.63% |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Avanos Medical | 3,771 |
| Bioventus | 970 |
| Relay Therapeutics | 323 |
| Ironwood Pharmaceuticals | 267 |
| Kura Oncology | 142 |
| Tyra Biosciences | 49 |
| Tectonic Therapeutic | 44 |
| Oculis Holding AG | 36 |
DNTH News
- 6 weeks ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results - GlobeNewsWire
- 6 weeks ago - Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - GlobeNewsWire
- 4 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - GlobeNewsWire
- 5 months ago - Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition - Seeking Alpha
- 6 months ago - Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) - GlobeNewsWire
- 6 months ago - Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) - GlobeNewsWire
- 7 months ago - Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire